Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies (NASDAQ:DBVT) announced completion of the last patient visit in the VITESSE Phase 3 trial of the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. The double-blind, placebo-controlled treatment phase is complete and the company remains on track to report topline data in Q4 2025.
The 12-month study enrolled 654 subjects randomized 2:1 across 86 sites in the U.S., Canada, Europe, the UK, and Australia. DBV described VITESSE as the largest treatment intervention study in peanut allergy and thanked investigators, patients, and caregivers for participation.
DBV Technologies (Nasdaq: DBVT) announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 2:00 p.m. ET in Boston, Massachusetts.
A live webcast will be available via the company’s Events page and an archived replay will be accessible for 90 days after the event. The presentation offers investors a direct opportunity to hear management remarks and strategic commentary.
DBV Technologies (Nasdaq: DBVT) appointed Kevin Trapp as Chief Commercial Officer, effective November 3, 2025, to lead global commercial strategy for the Viaskin® Peanut patch. DBV expects VITESSE Phase 3 topline results in Q4 2025 and plans a BLA submission for ages 4–7 in H1 2026, followed by a BLA submission for ages 1–3 in H2 2026. Mr. Trapp has 30+ years in biopharma and previously consulted for DBV since 2017.
DBVT (NYSE Euronext Paris, ISIN FR0010417345) disclosed its total number of shares and voting rights as of October 31, 2025. The company reported a total number of shares of 179,827,919.
The total gross voting rights equals 179,827,919 and the total net voting rights (excluding shares without voting rights) equals 179,741,847.
This information is provided under Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and was communicated on November 3, 2025.
DBV Technologies (Nasdaq:DBVT) announced the provisional appointment of Philina Lee, Ph.D. to its Board of Directors, effective October 30, 2025. She replaces Daniel Soland and will serve on the Board's Compensation Committee, increasing the Board to ten directors. The appointment is provisional and subject to shareholder ratification at the next annual meeting. Dr. Lee joins from Blueprint Medicines, where she led commercial operations including the launch and growth of AYVAKIT, and previously served on Fusion Pharmaceuticals' Board committees. DBV said her commercial and product-launch experience is expected to support advancement toward potential commercialization of VIASKIN Peanut for children and toddlers.
DBV Technologies (Nasdaq: DBVT) will participate in the ACAAI 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025. DBV will host a Product Theater on Nov 8, 2025 (11:35 a.m.–1:00 p.m. ET) titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy.”
The presentation will include a panel of allergists and details of a planned Phase 2 study assessing VIASKIN Peanut patch efficacy and safety to achieve ad lib peanut consumption in infants aged 6–12 months after a minimum of 3 years of treatment. Dr. Matthew Greenhawt will present EPOPEX end-of-study results on Nov 8 at 4:43 p.m. ET.
DBV will exhibit at booth #711, sponsor the FIT Bowl on Nov 8 (5:45–7:45 p.m. ET), and notes line-of-sight to a potential BLA filing for toddlers 1–3 years in the second half of next year under an Accelerated Approval Pathway.
DBV Technologies (Nasdaq: DBVT) announced an at-the-market sale of ADSs on October 29, 2025, raising approximately $30 million gross through Artisan via Citizens Capital Markets.
The transaction issues 2,142,860 ADSs (representing 10,714,300 ordinary shares), priced at $14.00 per ADS (subscription price €2.4063), and is expected to settle on October 31, 2025. New shares represent 6.34% of existing Euronext-listed shares and dilute existing holders by ~5.96%. Management estimates cash runway extended to end of Q4 2026; topline pediatric results and BLA timing reiterated for 4Q2025–1H/2H2026.
DBV Technologies (NASDAQ:DBVT) reported third quarter 2025 results with $69.8M cash and cash equivalents as of September 30, 2025, supporting an estimated cash runway into the third quarter of 2026. The company recorded a $102.1M net loss for the nine months ended September 30, 2025 and operating expenses of $107.0M over the same period.
Key financing actions include a 2025 PIPE (up to $306.9M) that delivered $125.5M on April 7, 2025 and potential aggregate proceeds of up to $181.4M if warrants are exercised; an ATM program of up to $150M and ~$30M gross received October 6, 2025. Management warns of substantial doubt about going concern and is pursuing additional financing options.
DBV Technologies (NASDAQ:DBVT) announced an At-The-Market sale of 2,307,692 ADSs (representing 11,538,460 ordinary shares) for gross proceeds of approximately $30 million at an at-the-market price of $13.00 per ADS (each ADS = 5 ordinary shares). The issuance price equates to a subscription price of €2.2264 per ordinary share (FX $1.1678/€1) and reflects a 3.41% discount to the prior Euronext Paris close. Settlement is expected on October 8, 2025, with ADSs admitted on Nasdaq and the new ordinary shares on Euronext Paris. The new shares represent 8.42% of existing Euronext-listed shares and imply ≈7.77% dilution on completion. A Form S-3 registration statement has been declared effective.
DBV Technologies (NASDAQ: DBVT) announced the immediate resignation of Daniel Soland from its Board of Directors. Soland, who joined the board in 2015, served on the Compensation Committee and contributed his expertise to the company's development of the VIASKIN® Peanut patch for peanut allergic children.
The Board will continue to operate with 9 remaining members while the Nomination and Governance Committee evaluates the timing and process for appointing a new member, subject to shareholder ratification at the next Annual General Meeting.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
